Rutgers, The State University of New Jersey
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Rutgers, The State University of New Jersey sits in the top decile of US sponsors by registered trial count (#86 of 15,742 sponsors by registered trial count).
Rutgers, The State University of New Jersey: 413 sponsored US clinical trials, 109 recruiting.
Rutgers, The State University of New Jersey sponsors 413 registered US clinical trials on ClinicalTrials.gov, 109 of them currently recruiting, and 196 completed. 35 of these trials are in Phase 3-4 (later-stage) and 104 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Autism Spectrum Disorder, with 6 trials.
Top-decile sponsor footprint
Rutgers, The State University of New Jersey ranks in the top decile of sponsors by registered trial count (#86 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
196 of 267 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (73.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
413 total, page 6 of 9
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
NCT03229278
Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant
NCT03102060
Project HERO: Health Empowerment & Recovery Outcomes
NCT03345563
Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
NCT03108911
Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment
NCT03228147
Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers
NCT03234478
Multi-dose Acetaminophen for Patients Undergoing General Anesthesia
NCT02832687
Does the Cerebroplacental Ratio (CPR) Predict Adverse Outcomes in Low Risk Pregnancies?
NCT03066726
Text Messaging Pilot Study
NCT03281356
Exercise Intensity and Video Games: Persons Post-stroke
NCT04538326
Myocardial Ischemia and Transfusion
NCT02981407
Physical Activity After a Normal Spontaneous or Cesarean Delivery
NCT02967016
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
NCT02748564
Focus Group in Collecting Feedbacks From Indoor Tanning Bed Users for Social Media-Delivered Intervention Development
NCT04179227
Novel Gallium 68 Citrate in Orthopedic Infections
NCT03123289
Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma
NCT03028948
Examining Persistence in Smokers With Schizophrenia
NCT03346291
A Cognitive Behavioral Stress Intervention for Women Who Smoke
NCT03077945
Therapeutic Epidural Patch Versus Pain Block in the Midface for Headache
NCT03112720
Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography
NCT02907814
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
NCT02621398
Sucralose and Lactisole Additions to OGTT in Humans
NCT05900193
Scopolamine Patch and Acupressure Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean Section
NCT02960113
Does Skyla Insertion Timing Impact Bleeding?
NCT03074903
Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures
NCT02637427
Air Pollution Study: The Effect of Ozone on the Lung
NCT02673775
Optimizing Clinical Use of Polymyxin B
NCT02682355
Peer Mentoring in Promoting Follow-up Care Self-Management in Younger Childhood Cancer Survivors
NCT02699996
eHealth Weight Loss Program in African American Breast Cancer Survivors
NCT02699983
Improve Hypertension Monitoring and Self-management by Using mHealth
NCT02632838
Project IMPACT: In-the-Moment Protection From Automatic Capture by Trigger
NCT02579317
Evaluating Interventions for Alcohol Use Disorder
NCT02409888
Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study
NCT02635347
Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease
NCT02076438
Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy
NCT03061175
Patient Education on Labor Analgesia Options
NCT02557555
Mobilization of Mesenchymal Stem Cells During Liver Transplantation
NCT02557724
Implementation of A Patient Centered Self-Management Program for Patients With Type 2 Diabetes
NCT02497170
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
NCT02526498
Acupuncture Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean
NCT02959840
Evaluation of Micropore"s SpiraLith Absorbents
NCT02550470
Telephone-Based Counseling for Depression in Parkinson's Disease
NCT02505737
Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy
NCT02420652
Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors
NCT02526511
Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
NCT02177838
Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer
NCT02458716
Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors
NCT02324621
Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer
NCT02324608
Oral ONC201 in Treating Patients With Advanced Solid Tumors
NCT02250781
Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
NCT02203578
What is open in the Rutgers, The State University of New Jersey pipeline
109 recruiting of 413 indexed (26% open); 196 completed (47%).
Phase mix: 35 late (III/IV) vs 104 early (I/II) (early-phase heavy).
Top condition: Autism Spectrum Disorder (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Rutgers, The State University of New Jersey: open-pipeline peers nationwide
Peers matched on 413 registered trials and 26% open enrollment, not the therapeutic-area sidebar.
Rutgers, The State University of New Jersey sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 413 trials (± recruiting share)
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
Sponsors near 26% open enrollment (± trial volume)
- Coherus Oncology · 27% recruiting · 15 trials
- NewAmsterdam Pharma · 27% recruiting · 15 trials
- Portland VA Medical Center · 27% recruiting · 15 trials
- White River Junction Veterans Affairs Medical Center · 27% recruiting · 15 trials
Related
What to do with this Rutgers, The State University of New Jersey page
413 registered trials is a research-attention snapshot, not an endorsement of Rutgers, The State University of New Jersey or any single study.
- 109 of Rutgers, The State University of New Jersey's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Autism Spectrum Disorder is the condition Rutgers, The State University of New Jersey studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Autism Spectrum Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Rutgers, The State University of New Jersey pipeline card: 413 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.